open access
Radiopotentiation of enzalutamide over human prostate cancer cells as assessed by real-time cell monitoring
open access
Abstract
Aim
To evaluate the radiopotentiation of enzalutamide in human prostate cancer cells.
Background
While radiotherapy is the first line of treatment for prostate cancer, androgen blockade therapies are demonstrating significant survival benefit as monotherapies. As androgen blockade can cause cell death by apoptosis, it is likely that androgen blockade will potentiate the cytotoxic activities of radiotherapy.
Materials and methods
Here, we tested the potential synergistic effects of these two treatments over two human metastatic prostate cancer cells by real-time cell analysis (RTCA), androgen-sensitive LNCaP cells (Lymph Node Carcinoma of the Prostate) and androgen-independent PC-3. Both cell lines were highly resistant to high doses of radiotherapy.
Results
A pre-treatment of LNCaP cells with IC50 concentrations of enzalutamide significantly sensitized them to radiotherapy through enhanced apoptosis. In contrast, enzalutamide resistant PC-3 cells were not sensitized to radiotherapy by androgen blockade.
Conclusions
These results provide evidence that the enzalutamide/radiotherapy combination could maximize therapeutic responses in patients with enzalutamide-sensitive prostate cancer.
Abstract
Aim
To evaluate the radiopotentiation of enzalutamide in human prostate cancer cells.
Background
While radiotherapy is the first line of treatment for prostate cancer, androgen blockade therapies are demonstrating significant survival benefit as monotherapies. As androgen blockade can cause cell death by apoptosis, it is likely that androgen blockade will potentiate the cytotoxic activities of radiotherapy.
Materials and methods
Here, we tested the potential synergistic effects of these two treatments over two human metastatic prostate cancer cells by real-time cell analysis (RTCA), androgen-sensitive LNCaP cells (Lymph Node Carcinoma of the Prostate) and androgen-independent PC-3. Both cell lines were highly resistant to high doses of radiotherapy.
Results
A pre-treatment of LNCaP cells with IC50 concentrations of enzalutamide significantly sensitized them to radiotherapy through enhanced apoptosis. In contrast, enzalutamide resistant PC-3 cells were not sensitized to radiotherapy by androgen blockade.
Conclusions
These results provide evidence that the enzalutamide/radiotherapy combination could maximize therapeutic responses in patients with enzalutamide-sensitive prostate cancer.
Keywords
Enzalutamide; Radiotherapy; Apoptosis; Prostate cancer; Androgen blockade
About this articleTitle
Radiopotentiation of enzalutamide over human prostate cancer cells as assessed by real-time cell monitoring
Journal
Reports of Practical Oncology and Radiotherapy
Issue
Pages
221-226
Published online
2019-03-01
DOI
10.1016/j.rpor.2019.02.002
Bibliographic record
Rep Pract Oncol Radiother 2019;24(2):221-226.
Keywords
Enzalutamide
Radiotherapy
Apoptosis
Prostate cancer
Androgen blockade
Authors
Marta Barrado
Idoia Blanco-Luquin
Paola Andrea Navarrete
Ignacio Visus
David Guerrero-Setas
David Escors
Grazyna Kochan
Fernando Arias